Federated Hermes’s Kindred Biosciences, Inc. KIN Stock Holding History

Federated Hermes’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-165	Closed	-$1K	–	2414
2020 Q4	$1K	Buy	+165	New	+$671	﹤0.01%	2217
2019 Q2	–	Sell	-680	Closed	-$7K	–	2259
2019 Q1	$7K	Sell	680 -1,584	-70%	-$16.1K	﹤0.01%	1935
2018 Q4	$25K	Sell	2,264 -322	-12%	-$4.06K	﹤0.01%	1735
2018 Q3	$36K	Buy	2,586 +287	+12%	+$3.88K	﹤0.01%	1781
2018 Q2	$24K	Sell	2,299 -15	-0.6%	-$146	﹤0.01%	1781
2018 Q1	$20K	Sell	2,314 -41	-2%	-$360	﹤0.01%	1769
2017 Q4	$22K	Sell	2,355 -722	-23%	-$5.64K	﹤0.01%	1757
2017 Q3	$24K	Buy	3,077 +1,334	+77%	+$10K	﹤0.01%	1726
2017 Q2	$15K	Buy	1,743 +868	+99%	+$6.23K	﹤0.01%	1788
2017 Q1	$6K	Buy	875 +279	+47%	+$1.75K	﹤0.01%	1912
2016 Q4	$3K	Buy	+596	New	+$2.88K	﹤0.01%	2001

Other funds holding KIN

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BCPEMI

Bain Capital Public Equity Management II Boston, Massachusetts $62.1M AUM 25.46% 1-Year Est. Return

Federated Hermes's KIN Position: Q1 2021 in Review

Federated Hermes sold out of Kindred Biosciences, Inc. (KIN) in Q1 2021, closing a stake of 165 shares — an estimated $1K sold.

Federated Hermes first reported a position in KIN in Q4 2016 and held it in 11 quarters. The position peaked at $36K in Q3 2018. 84 funds tracked by Wall St. Rank hold KIN as of Q1 2021.

Federated Hermes reported no remaining Kindred Biosciences, Inc. position as of Q1 2021 after selling out during the quarter.
Federated Hermes sold 165 Kindred Biosciences, Inc. shares in Q1 2021, an estimated $1K.
Federated Hermes first reported a position in Kindred Biosciences, Inc. in Q4 2016 and held it in 11 quarters.
Federated Hermes's Kindred Biosciences, Inc. position peaked at $36K in Q3 2018.
84 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q1 2021.

Based on Federated Hermes's 13F filing for Q1 2021, filed 13 May 2021.